SGLT2 and DPP4 inhibitors improve Alzheimer’s disease–like pathology and cognitive function through distinct mechanisms in a T2D–AD mouse model

SGLT2 and DPP4 inhibitors improve Alzheimer’s disease–like pathology and cognitive function through distinct mechanisms in a T2D–AD mouse model

Alzheimer’s disease (AD) and type 2 diabetes mellitus (T2D) share common features, including insulin resistance. Brain insulin resistance has been implicated as a key factor in the pathogenesis of AD. Recent studies have demonstrated that anti-diabetic drugs sodium–glucose cotransporter-2 inhibitor...

Full description

Bibliographic Details
Main Authors:	A Young Sim, Da Hyun Choi, Jong Youl Kim, Eun Ran Kim, A-ra Goh, Yong-ho Lee, Jong Eun Lee
Format:	Article
Language:	English
Published:	Elsevier 2023-12-01
Series:	Biomedicine & Pharmacotherapy
Subjects:	Alzheimer’s disease Type 2 diabetes mellitus Sodium–glucose cotransporter-2 inhibitor Dipeptidyl peptidase-4 inhibitor Hyperphosphorylated tau Amyloid β
Online Access:	http://www.sciencedirect.com/science/article/pii/S0753332223015536

Similar Items

Patients’ Preference Between DPP4i and SGLT2i for Type 2 Diabetes Treatment: A Cross-Sectional Evaluation
by: Costa Gil JE, et al.
Published: (2022-05-01)

Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease
by: Sook Jung Lee, et al.
Published: (2019-12-01)

Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
by: A Young Sim, et al.
Published: (2021-08-01)

Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale
by: Yassin SA, et al.
Published: (2017-03-01)

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
by: Jong Ho Kim, et al.
Published: (2016-04-01)

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
by: Nasser Mikhail
Published: (2008-12-01)

Sodium glucose cotransporter‐2 inhibitor was associated with an improvement in left ventricular systolic function in patients with type 2 diabetes mellitus with impaired left ventricular systolic function
by: Yi‐Hsin Chan, et al.
Published: (2020-10-01)

Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes
by: Jin-Sun Chang, et al.
Published: (2013-02-01)

The regulatory role of DPP4 in atherosclerotic disease
by: Lihua Duan, et al.
Published: (2017-06-01)

The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
by: Ann Wan-Chin Ling, et al.
Published: (2020-11-01)

Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis
by: Jung Min Lee, et al.
Published: (2019-10-01)

New Drugs for Type 2 Diabetes: New Hopes and New Concerns About the Skeleton
by: Zehra Berberoglu
Published: (2016-10-01)

Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity
by: Jae-Geun Lee, et al.
Published: (2011-04-01)

Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus
by: Choi YJ, et al.
Published: (2019-08-01)

Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis
by: Dan Liu, et al.
Published: (2019-03-01)

Abelmoschus esculentus subfractions attenuate Aβ and tau by regulating DPP-4 and insulin resistance signals
by: Chien-Ning Huang, et al.
Published: (2020-12-01)

Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients
by: Young-Hwan Park, et al.
Published: (2024-03-01)

Acquired Haemophilia A in DPP4 Inhibitor-induced Bullous Pemphigoid as Immune Reconstitution Syndrome
by: Seiko Sugiyama, et al.
Published: (2020-06-01)

by: Jong-Ha Baek, et al.
Published: (2016-12-01)

Teneligliptin in management of type 2 diabetes mellitus
by: Sharma SK, et al.
Published: (2016-08-01)

Endogenous GLP-1 levels play an important role in determining the efficacy of DPP-IV Inhibitors in both prediabetes and type 2 diabetes
by: Shiau Chin Chong, et al.
Published: (2022-10-01)

A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin
by: Hiroshi Nomoto, et al.
Published: (2017-07-01)

The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study
by: Shin S, et al.
Published: (2016-03-01)

The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study
by: Yi-Hsin Chan, et al.
Published: (2022-06-01)

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus
by: Sung-Ho Kim, et al.
Published: (2016-09-01)

A case of anti-BP230 antibody-positive bullous pemphigoid receiving DPP-4 inhibitor
by: Kaori Sawada, et al.
Published: (2021-01-01)

The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo
by: Masako Uchii, et al.
Published: (2017-11-01)

Risk of Pancreatic Cancer and Use of Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matching Analysis
by: Mee Kyoung Kim, et al.
Published: (2023-08-01)

Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION)
by: Byung Wan Lee, et al.
Published: (2023-06-01)

Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database
by: Sunghwan Suh, et al.
Published: (2015-06-01)

Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double‐blind, placebo‐controlled study
by: Linong Ji, et al.
Published: (2021-04-01)

Phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
by: Linong Ji, et al.
Published: (2021-04-01)

Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
by: In-Chang Hwang, et al.
Published: (2020-05-01)

Effects of metformin and alogliptin on body composition in people with type 2 diabetes
by: Yumie Takeshita, et al.
Published: (2019-05-01)

Saxagliptin for type 2 diabetes
by: Chacra
Published: (2010-09-01)

Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study
by: Young-Gun Kim, et al.
Published: (2018-06-01)

Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer
by: Chintan Shah, et al.
Published: (2020-03-01)

The roles of dipeptidyl peptidase-4 inhibitors in prognosis of COVID-19 infection in patients with type 2 diabetes mellitus
by: Mohammad Sadidi, et al.
Published: (2022-01-01)

An open-label pilot study on preventing glucocorticoid-induced diabetes mellitus with linagliptin
by: Yoshia Miyawaki, et al.
Published: (2018-10-01)

Switching to Versus Addition of Incretin‐Based Drugs Among Patients With Type 2 Diabetes Taking Sodium‐Glucose Cotransporter‐2 Inhibitors
by: Kristy T. K. Lau, et al.
Published: (2022-04-01)